Tormenta de citoquinas: reacción adversa inhabitual por rituximab. Caso clínico

Rituximab is a plausible alternative first-line treatment of ANCA-associated vasculitis. Adverse effects related to its infusion are common and usually have a benign course. However, there have been reports of refractory cardiogenic shock simulating septic shock. We report an 81-year-old male with t...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Palma,Estefanía, González,Vicente, Grünholz,Daniela, Landaeta,María, Mallea,María, Pérez,José, Armstrong,Tomás
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2017
Materias:	Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Drug-Related Side Effects and Adverse Reactions Rituximab Shock
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872017000200015
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872017000200015
record_format	dspace
spelling	oai:scielo:S0034-988720170002000152017-05-02Tormenta de citoquinas: reacción adversa inhabitual por rituximab. Caso clínicoPalma,EstefaníaGonzález,VicenteGrünholz,DanielaLandaeta,MaríaMallea,MaríaPérez,JoséArmstrong,Tomás Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Drug-Related Side Effects and Adverse Reactions Rituximab Shock Rituximab is a plausible alternative first-line treatment of ANCA-associated vasculitis. Adverse effects related to its infusion are common and usually have a benign course. However, there have been reports of refractory cardiogenic shock simulating septic shock. We report an 81-year-old male with the diagnosis of ANCA associated vasculitis. Rituximab 500 mg was administered intravenously for a relapse. The infusion proceeded without incident. However, 24 hours after its administration the patient began with fever, chills, coughing and strong malaise. The patient was transferred to the critical patient unit where a septic shock was suspected and resuscitative measures were started. However, the fast response to moderate doses of vasoactive drugs and complementary tests did not support an infectious etiology for the shock. Antimicrobials were discontinued and systemic corticosteroids were maintained, achieving remission of the symptoms. Shock as an unusual adverse reaction to Rituximab was suspected.info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.145 n.2 20172017-02-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872017000200015es10.4067/S0034-98872017000200015
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Drug-Related Side Effects and Adverse Reactions Rituximab Shock
spellingShingle	Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Drug-Related Side Effects and Adverse Reactions Rituximab Shock Palma,Estefanía González,Vicente Grünholz,Daniela Landaeta,María Mallea,María Pérez,José Armstrong,Tomás Tormenta de citoquinas: reacción adversa inhabitual por rituximab. Caso clínico
description	Rituximab is a plausible alternative first-line treatment of ANCA-associated vasculitis. Adverse effects related to its infusion are common and usually have a benign course. However, there have been reports of refractory cardiogenic shock simulating septic shock. We report an 81-year-old male with the diagnosis of ANCA associated vasculitis. Rituximab 500 mg was administered intravenously for a relapse. The infusion proceeded without incident. However, 24 hours after its administration the patient began with fever, chills, coughing and strong malaise. The patient was transferred to the critical patient unit where a septic shock was suspected and resuscitative measures were started. However, the fast response to moderate doses of vasoactive drugs and complementary tests did not support an infectious etiology for the shock. Antimicrobials were discontinued and systemic corticosteroids were maintained, achieving remission of the symptoms. Shock as an unusual adverse reaction to Rituximab was suspected.
author	Palma,Estefanía González,Vicente Grünholz,Daniela Landaeta,María Mallea,María Pérez,José Armstrong,Tomás
author_facet	Palma,Estefanía González,Vicente Grünholz,Daniela Landaeta,María Mallea,María Pérez,José Armstrong,Tomás
author_sort	Palma,Estefanía
title	Tormenta de citoquinas: reacción adversa inhabitual por rituximab. Caso clínico
title_short	Tormenta de citoquinas: reacción adversa inhabitual por rituximab. Caso clínico
title_full	Tormenta de citoquinas: reacción adversa inhabitual por rituximab. Caso clínico
title_fullStr	Tormenta de citoquinas: reacción adversa inhabitual por rituximab. Caso clínico
title_full_unstemmed	Tormenta de citoquinas: reacción adversa inhabitual por rituximab. Caso clínico
title_sort	tormenta de citoquinas: reacción adversa inhabitual por rituximab. caso clínico
publisher	Sociedad Médica de Santiago
publishDate	2017
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872017000200015
work_keys_str_mv	AT palmaestefania tormentadecitoquinasreaccionadversainhabitualporrituximabcasoclinico AT gonzalezvicente tormentadecitoquinasreaccionadversainhabitualporrituximabcasoclinico AT grunholzdaniela tormentadecitoquinasreaccionadversainhabitualporrituximabcasoclinico AT landaetamaria tormentadecitoquinasreaccionadversainhabitualporrituximabcasoclinico AT malleamaria tormentadecitoquinasreaccionadversainhabitualporrituximabcasoclinico AT perezjose tormentadecitoquinasreaccionadversainhabitualporrituximabcasoclinico AT armstrongtomas tormentadecitoquinasreaccionadversainhabitualporrituximabcasoclinico
_version_	1718436931375726592

Tormenta de citoquinas: reacción adversa inhabitual por rituximab. Caso clínico

Ejemplares similares